FDA Expands Indication of Regional Analgesic to Reduce Postsurgical Pain Without Opioids
Pharmacy Times
NOVEMBER 13, 2023
Bupivacaine liposome injectable suspension was shown to reduce opioid use after surgery and significantly improve pain.
Mon.Nov 13, 2023
156 
FDA Grants Priority Review to Liso-Cel in Relapsed/Refractory CLL/SLL
Drug Topics
NOVEMBER 13, 2023
The FDA acceptance marks the first step in addressing the unmet need for a lasting treatment option for patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Life expectancy for men in U.S. falls to 73 years — six years less than for women, per study
STAT
NOVEMBER 13, 2023
The life expectancy of men in the U.S. is nearly six years shorter than that of women, according to new research published on Monday in JAMA Internal Medicine. At least partially as a consequence of over 1 million Covid-19 deaths, life expectancy in the U.S. has declined significantly over the past few years, falling from 78.8 years in 2019 to 77 in 2020 and 76.1 in 2022 — undoing over two decades of progress.
First OTC Rapid Antigen Test for COVID-19 Cleared By FDA
Drug Topics
NOVEMBER 13, 2023
The test is also the first OTC rapid antigen test cleared for any infectious disease.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Study suggests Covid rebound is far more common with Paxlovid than without
STAT
NOVEMBER 13, 2023
A small and preliminary study published Monday seems to indicate that patients receiving the drug Paxlovid are far more likely to experience Covid rebound than those who did not take it. That conclusion runs counter to previous statements by Pfizer, which makes Paxlovid, and by researchers at the Food and Drug Administration who have argued that while it is not uncommon for people with Covid to have symptoms reemerge after they seem to have recovered, it is not clear that Paxlovid increases the
Prior authorization and other regulatory burdens have increased since last year, practices tell MGMA
Fierce Healthcare
NOVEMBER 13, 2023
Nine in 10 polled medical practices say their regulatory burden has increased over the past year with prior authorization, audits and appeals, the Medicare Quality Payment Program (QPP) and require | The latest annual poll of practices' regulatory burden outlined prior authorization, audits and appeals, Medicare QPP and other leading pain points that physicians say are weighing down theor staff and ability to deliver care.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
Data Show Effect of Dietary Sodium Reduction on Blood Pressure Was Comparable to First-Line Medication
Pharmacy Times
NOVEMBER 13, 2023
Clinically meaningful lowering of blood pressure through reduction in dietary sodium was achieved safely and rapidly in 1 week in a middle-aged and elderly cohort.
The U.K. just cleared a drug to prevent breast cancer. U.S. women may not know it’s already an option
STAT
NOVEMBER 13, 2023
The news that the U.K. has approved a preventive drug for post-menopausal women at risk of developing breast cancer wasn’t a shock to breast medical oncologist Abenaa Brewster. But the fact that a patient in her breast cancer prevention clinic hadn’t ever heard of such a possibility before was. “I thought to myself, ‘Oh, my God, I can’t believe a woman in America is being educated about preventive therapy from European use,’ because for the last 25 years
Data Show Benefit of Intensive Blood Pressure Reduction Is Consistent in East Asian Population With Hypertension, High Cardiovascular Risk
Pharmacy Times
NOVEMBER 13, 2023
The SPRINT trial was the first to demonstrate the benefit of further reduction in blood pressure, but it included a limited Asian population and excluded patients with diabetes or history of stroke.
NYU radiologists tackle the challenge of making MRI machines less expensive
STAT
NOVEMBER 13, 2023
How many radiologists does it take to build a working MRI from scratch? New York University radiologists Leeor Alon and Tobias Block wanted to find out. The two hosted 50 researchers in New York City last month, and over the course of five days, managed to build a small, low-field MRI. Alon and Block are currently fine-tuning its imaging abilities. The overarching message of the gathering: MRIs don’t need to be as expensive as they currently are.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Where old pathways to innovative cancer care fall short, a new model emerges
pharmaphorum
NOVEMBER 13, 2023
Where old pathways to innovative cancer care fall short, a new model emerges Mike.
STAT+: Eli Lilly’s chief scientist on new obesity drug data, gene editing, and a potential new heart drug
STAT
NOVEMBER 13, 2023
PHILADELPHIA — In a sense, the annual meeting of the American Heart Association wasn’t a huge one for Eli Lilly. Its biggest news was about a very early study of a drug to lower blood levels Lp(a), a protein related to cholesterol that is mainly being watched by lipidologists and drug company analysts. But in another way, the future of Lilly, now the biggest drug company by market capitalization, hung in the balance.
Pharmacy Focus: Policy Edition - Navigating the Reimbursement Maze
Pharmacy Times
NOVEMBER 13, 2023
Tune in to this episode of Pharmacy Focus: Policy Edition for an update on the ever-evolving landscape of pharmacy reimbursements, pharmacy benefit manager reform, and direct and indirect remuneration fees.
STAT+: Novo Nordisk wants to be a cardiovascular company, too, with sights set on inflammation
STAT
NOVEMBER 13, 2023
PHILADELPHIA – Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster drugs Ozempic and Wegovy, now also wants to be a major player in heart disease. The landmark Select trial presented over the weekend – which showed Wegovy significantly cut the risk of heart complications – is just one of many efforts by the Danish drugmaker to expand into the cardiovascular space.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Implement Strategies Now to Prevent Patient Death From Accidental Daily Methotrexate Dosing
Pharmacy Times
NOVEMBER 13, 2023
Specifying a day of the week to take the medication could help avoid inadvertent daily dosing
STAT+: Michigan bill that would pare back pharma liability shield law moves closer to enactment
STAT
NOVEMBER 13, 2023
A one-of-a-kind law in Michigan that prevents the state government and residents from suing pharmaceutical companies over injuries caused by their medicines is poised to be pared back. A bill designed to allow product liability lawsuits to be filed against drug companies passed the Michigan Senate last month and then passed the House last week. The legislation , which won overwhelming majorities in both chambers but was opposed by the Michigan Chamber of Commerce and a pharmaceutical industry tr
Data Show Lepodisiran Was Well Tolerated, Substantially Lowered Lipoprotein (a)
Pharmacy Times
NOVEMBER 13, 2023
Elevated Lp(a), which was previously untreatable, may become treatable in the near future, according to the study investigator.
STAT+: Patients loved Carbon Health’s diabetes program. That couldn’t save it
STAT
NOVEMBER 13, 2023
A diabetes diagnosis was not what Jason had in mind when he set out on a cross-country road trip with his family in the fall of 2021. He had been heavy since he was a kid, but he always had felt pretty healthy — until getting home to the San Francisco Bay Area, when he started to notice his body doing strange things. “It kind of came out of nowhere,” said Jason, who asked to keep his last name private.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
SELECT Trial Data Show Benefit of Semaglutide in Patients With Obesity
Pharmacy Times
NOVEMBER 13, 2023
The SELECT trial expands on existing literature that have shown safety and cardiovascular benefit in individuals with diabetes to now also show benefit in obesity.
Opinion: Congress must reauthorize the National Advisory Committee for Seniors and Disasters
STAT
NOVEMBER 13, 2023
With the election of Rep. Mike Johnson as speaker of the House, the urgent and important work of passing appropriations and vital national security legislation is now advancing. But it is also the time to address additional important issues affecting the well-being of Americans, such as one highlighted during the Covid-19 pandemic as well as recent wildfires and hurricanes: the care and support for America’s most vulnerable.
Upcoming Phase 3 Trials to Evaluate Efficacy, Safety of Milvexian in Patients with Cardiovascular Conditions
Pharmacy Times
NOVEMBER 13, 2023
Harrington discusses how the performance of milvexian in prior phase 2 trials focused on different patient populations creates the foundation for future research.
Victoria Atkins replaces Barclay as UK health secretary
pharmaphorum
NOVEMBER 13, 2023
Victoria Atkins replaces Barclay as UK health secretary Phil.
Novo Nordisk says Wegovy can help heart disease patients—and not just because it produces weight loss
Fierce Pharma
NOVEMBER 13, 2023
Novo Nordisk has made a splash with its GLP-1 drugs that have allowed patients to achieve significant weight loss. | Novo Nordisk has made a splash with its GLP-1 drugs that have allowed patients to achieve significant weight loss. Now the Danish company appears on the verge of another breakthrough, showing that the use of its obesity treatment Wegovy can reduce the risk of heart attack.
Akili says OTC switch for ADHD DTx leads to sales rise
pharmaphorum
NOVEMBER 13, 2023
Akili says OTC switch for ADHD DTx leads to sales rise Phil.
Humans can’t shake the mosquito threat. Here’s what pharma has in the pipeline.
PharmaVoice
NOVEMBER 13, 2023
The arsenal against the world’s deadliest creature is growing and a universal vaccine is in the works.
UCB on course for approval of gMG drug Rystiggo in EU
pharmaphorum
NOVEMBER 13, 2023
UCB on course for approval of gMG drug Rystiggo in EU Phil.
NACDS’ health, wellness initiatives take center stage at 2023 Milken Institute Future of Health Summit
Drug Store News
NOVEMBER 13, 2023
NACDS’ initiatives regarding health and wellness were on display at the 2023 Milken Institute Future of Health Summit.
ADCs shine at ESMO ’23, as pharma makes case for early immunotherapy interventions
pharmaphorum
NOVEMBER 13, 2023
ADCs shine at ESMO ’23, as pharma makes case for early immunotherapy interventions Mike.
Walgreens Boots Alliance sells shares of Cencora for $674M of initial proceeds
Drug Store News
NOVEMBER 13, 2023
Walgreens Boots Alliance said there will be no changes to its ongoing collaboration and long-term strategic partnership with Cencora.
Half a year later, Teva's 'pivot to growth' strategy appears to be bearing fruit
Fierce Pharma
NOVEMBER 13, 2023
Six months on, Teva’s new “pivot to growth” strategy appears to be paying off. | In 2023’s third quarter, the Israeli-American generics giant reported global sales of $3.9 billion, up 7% from the same period in 2022. The company credited that growth to the strong momentum behind its branded meds Austedo and Ajovy, plus a “stable and sustainable generics business” in the U.S. that’s also seen “continued growth” in Europe and other international markets.
Organic India launches Tulsi Tumeric Chai
Drug Store News
NOVEMBER 13, 2023
The company said Tulsi Turmeric Chai, the newest tea flavor, is one in which classic chai spices meet golden turmeric.
Rivaroxaban Demonstrates Favorable Benefit-Risk Profile in Fragile Populations with Peripheral Arterial Disease
Pharmacy Times
NOVEMBER 13, 2023
Bonaca also notes that pharmacists can play a key role in educating patients and clinicians about the appropriate use and dosing of antithrombotic drugs for vascular protection.
Equity for Women in Healthcare: 131 Years is Too Long to Wait
PharmExec
NOVEMBER 13, 2023
Closing the gender gap in pharma—and how we get there together.
Let's personalize your content